BioCentury | Jul 29, 2013
Company News

Cureveda, NIH autoimmune news

...nuclear factor (erythroid-derived 2)-like 2 ( NFE2L2 ; NRF2 ) activator is in preclinical development. Cureveda...
...Public Health faculty members Shyam Biswal, Rajesh Thimmulappa and Christy Wyskiel founded Cureveda in 2010. Cureveda...
...pathway to treat chronic obstructive pulmonary disease (COPD). GSK does not have rights to VEDA-1209. Cureveda LLC...
Items per page:
1 - 1 of 1
BioCentury | Jul 29, 2013
Company News

Cureveda, NIH autoimmune news

...nuclear factor (erythroid-derived 2)-like 2 ( NFE2L2 ; NRF2 ) activator is in preclinical development. Cureveda...
...Public Health faculty members Shyam Biswal, Rajesh Thimmulappa and Christy Wyskiel founded Cureveda in 2010. Cureveda...
...pathway to treat chronic obstructive pulmonary disease (COPD). GSK does not have rights to VEDA-1209. Cureveda LLC...
Items per page:
1 - 1 of 1